Use: Labeled indications
- INDICATIONS AND USAGE UNASYN is indicated for the treatment of infections due to susceptible strains of the designated microorganisms in the conditions listed below.
Full indications and usage US FDA label
INDICATIONS AND USAGE UNASYN is indicated for the treatment of infections due to susceptible strains of the designated microorganisms in the conditions listed below. Skin and Skin Structure Infections caused by beta-lactamase producing strains of Staphylococcus aureus, Escherichia coli, Efficacy for this organism in this organ system was studied in fewer than 10 infections.
Klebsiella spp. (including K. pneumoniae), Proteus mirabilis, Bacteroides fragilis, Enterobacter spp., and Acinetobacter calcoaceticus. NOTE: For information on use in pediatric patients (see PRECAUTIONS–Pediatric Use and CLINICAL STUDIES sections). Intra-Abdominal Infections caused by beta-lactamase producing strains of Escherichia coli, Klebsiella spp.
(including K. pneumoniae), Bacteroides spp. (including B. fragilis), and Enterobacter spp. Gynecological Infections caused by beta-lactamase producing strains of Escherichia coli, and Bacteroides spp. (including B. fragilis). While UNASYN is indicated only for the conditions listed above, infections caused by ampicillin-susceptible organisms are also amenable to treatment with UNASYN due to its ampicillin content.
Therefore, mixed infections caused by ampicillin-susceptible organisms and beta-lactamase producing organisms susceptible to UNASYN should not require the addition of another antibacterial. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify the organisms causing infection and to determine their susceptibility to UNASYN.
Therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies when there is reason to believe the infection may involve any of the beta-lactamase producing organisms listed above in the indicated organ systems. Once the results are known, therapy should be adjusted if appropriate.
To reduce the development of drug-resistant bacteria and maintain effectiveness of UNASYN and other antibacterial drugs, UNASYN should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy.
In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Contraindications
- Serious hypersensitivity (anaphylaxis, Stevens-Johnson syndrome) to ampicillin, sulbactam or other beta-lactams
- Previous cholestatic jaundice or hepatic dysfunction with ampicillin-sulbactam
Contraindications (US label) US FDA label
CONTRAINDICATIONS The use of UNASYN is contraindicated in individuals with a history of serious hypersensitivity reactions (e.g., anaphylaxis or Stevens-Johnson syndrome) to ampicillin, sulbactam or to other beta-lactam antibacterial drugs (e.g., penicillins and cephalosporins). UNASYN is contraindicated in patients with a previous history of cholestatic jaundice/hepatic dysfunction associated with UNASYN.
Dosing: Adult
- Adults: 1.5 g (ampicillin 1 g + sulbactam 0.5 g) to 3 g (2 g + 1 g) IV or IM every 6 hours
- Maximum: Sulbactam 4 g/day
- CrCl below 30 mL/min/1.73 m2: 15–29: every 12 hours; 5–14: every 24 hours
Dosage and administration (US label) US FDA label
DOSAGE AND ADMINISTRATION UNASYN may be administered by either the IV or the IM routes. For IV administration, the dose can be given by slow intravenous injection over at least 10–15 minutes or can also be delivered in greater dilutions with 50 mL–100 mL of a compatible diluent as an intravenous infusion over 15–30 minutes.
(see DIRECTIONS FOR USE-Preparation for Intravenous Use section). UNASYN may be administered by deep intramuscular injection (see DIRECTIONS FOR USE-Preparation for Intramuscular Injection section). The recommended adult dosage of UNASYN is 1.5 g (ampicillin 1 g and sulbactam 0.5 g) to 3 g (ampicillin 2 g and sulbactam 1 g) every six hours.
This 1.5 g to 3 g range represents the total of ampicillin content plus the sulbactam content of UNASYN, and corresponds to a range of 1 g ampicillin and 0.5 g sulbactam to 2 g ampicillin and 1 g sulbactam. The total dose of sulbactam should not exceed 4 g per day. Pediatric Patients 1 Year of Age or Older The recommended daily dose of UNASYN in pediatric patients is 300 mg per kg of body weight administered via intravenous infusion in equally divided doses every 6 hours.
This 300 mg/kg/day dosage represents the total ampicillin content plus the sulbactam content of UNASYN, and corresponds to 200 mg ampicillin and 100 mg sulbactam per kg per day. The safety and efficacy of UNASYN administered via intramuscular injection in pediatric patients have not been established. Pediatric patients weighing 40 kg or more should be dosed according to adult recommendations, and the total dose of sulbactam should not exceed 4 g per day.
The course of intravenous therapy should not routinely exceed 14 days. In clinical trials, most pediatric patients received a course of oral antimicrobials following initial treatment with intravenous UNASYN (see CLINICAL STUDIES section). Impaired Renal Function In patients with impairment of renal function the elimination kinetics of ampicillin and sulbactam are similarly affected, hence the ratio of one to the other will remain constant whatever the renal function.
The dose of UNASYN in such patients should be administered less frequently in accordance with the usual practice for ampicillin and according to the following recommendations: TABLE 3 UNASYN Dosage Guide for Patients with Renal Impairment Creatinine Clearance (mL/min/1.73 m²) Ampicillin and Sulbactam Half-Life (Hours) Recommended UNASYN Dosage ≥30 1 1.5 g to 3 g every 6 to 8 hours 15–29 5 1.5 g to 3 g every 12 hours 5–14 9 1.5 g to 3 g every 24 hours When only serum creatinine is available, the following formula (based on sex, weight, and age of the patient) may be used to convert this value into creatinine clearance. The serum creatinine should represent a steady state of renal function.
Males Weight (kg) x (140 – age) 72 x serum creatinine Females 0.85 x above value
Dosing: Altered kidney function
Ampicillin and sulbactam are both about 75% to 85% excreted unchanged in urine, and kidney impairment slows both equally, so their ratio stays constant. The US label gives 1.5 to 3 g at longer intervals as creatinine clearance (CrCl) falls: every 6 to 8 hours at 30 or more, every 12 hours at 15–29 and every 24 hours at 5–14 mL/min/1.73 m2. The label gives no dialysis dose.
Kidney function measure: Label uses CrCl in mL/min/1.73 m2 (Cockcroft–Gault formula quoted); bands at 30 and 15. The mL/min/1.73 m2 unit is the label's own convention and is kept verbatim.
Show full dosing details
- CrCl ≥60 mL/min/1.73 m2
- 1.5 to 3 g every 6 hours (usual); the label's CrCl 30 or more row allows every 6 to 8 hours (label Table 3).
- CrCl 30–59 mL/min/1.73 m2
- CrCl 30 or more: 1.5 to 3 g every 6 to 8 hours (label Table 3).
- CrCl 15–29 mL/min/1.73 m2
- CrCl 15–29: 1.5 to 3 g every 12 hours (label Table 3).
- CrCl <15 mL/min/1.73 m2 (not on dialysis)
- CrCl 5–14: 1.5 to 3 g every 24 hours (label Table 3). Below 5: not stated; specialist input.
- Hemodialysis (intermittent)
- No hemodialysis dosing in label. Ampicillin is removed by hemodialysis, and sulbactam probably is (label overdose section). Specialist input.
- Peritoneal dialysis
- No peritoneal dialysis dosing in label. For PD-associated peritonitis (ISPD 2022): continuous intraperitoneal loading dose 1,000 mg/500 mg, then maintenance 133.3 mg/66.7 mg (ampicillin/sulbactam, as printed in ISPD Table 5); no intermittent dose listed. Specialist input.
- CRRT
- Not in label. Li 2020 (Table 3), sulbactam component: CVVH ultrafiltration 30 mL/kg/h, CVVHD dialysate 1 L/h, or CVVHDF combined 1 L/h, 1 g every 8 hours (1 g sulbactam = ampicillin-sulbactam 3 g); higher doses may be needed for less susceptible organisms, and Li suggests drug level monitoring.
- Dialyzable? Ampicillin: yes, removed by hemodialysis. Sulbactam: probably, from its size, protein binding and kinetics (label). Protein binding: ampicillin 28%, sulbactam 38%.
- Monitoring CrCl for dose; seizures with high CSF beta-lactam levels (label overdose section); liver tests (history of cholestatic jaundice is a contraindication); rash; diarrhea (CDAD).
Children (kidney dosing)
Show full dosing details
- eGFR ≥60
- Usual pediatric dose (label).
- eGFR 30–59
- No pediatric kidney dosing in label. Specialist input.
- eGFR 15–29
- No pediatric kidney dosing in label. Specialist input.
- eGFR <15 (not on dialysis)
- No pediatric kidney dosing in label. Specialist input.
- Hemodialysis (intermittent)
- No pediatric kidney dosing in label. Specialist input.
- Peritoneal dialysis
- No pediatric kidney dosing in label. Specialist input.
- CRRT
- No pediatric kidney dosing in label. Specialist input.
Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.
renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.
US label text: Renal impairment US FDA label
Impaired Renal Function In patients with impairment of renal function the elimination kinetics of ampicillin and sulbactam are similarly affected, hence the ratio of one to the other will remain constant whatever the renal function. The dose of UNASYN in such patients should be administered less frequently in accordance with the usual practice for ampicillin and according to the following recommendations: TABLE 3 UNASYN Dosage Guide for Patients with Renal Impairment Creatinine Clearance (mL/min/1.73 m²) Ampicillin and Sulbactam Half-Life (Hours) Recommended UNASYN Dosage ≥30 1 1.5 g to 3 g every 6 to 8 hours 15–29 5 1.5 g to 3 g every 12 hours 5–14 9 1.5 g to 3 g every 24 hours When only serum creatinine is available, the following formula (based on sex, weight, and age of the patient) may be used to convert this value into creatinine clearance.
The serum creatinine should represent a steady state of renal function. Males Weight (kg) x (140 – age) 72 x serum creatinine Females 0.85 x above value
Dosing: Pediatric
- Approved ages
- 1 year and older (skin and skin structure infections, IV) (label).
- Usual dose
- 300 mg/kg/day IV (200 mg ampicillin plus 100 mg sulbactam per kg), divided every 6 hours; 40 kg or more: adult dose (label).
- Maximum dose
- Sulbactam 4 g/day; IV course usually not over 14 days (label).
Kidney dosing in children: see Dosing: Altered kidney function.
renalcarematters.com, reviewedPediatric use (US label) US FDA label
Pediatric Use The safety and effectiveness of UNASYN have been established for pediatric patients one year of age and older for skin and skin structure infections as approved in adults. Use of UNASYN in pediatric patients is supported by evidence from adequate and well-controlled studies in adults with additional data from pediatric pharmacokinetic studies, a controlled clinical trial conducted in pediatric patients and post-marketing adverse events surveillance (see CLINICAL PHARMACOLOGY, INDICATIONS AND USAGE, ADVERSE REACTIONS, DOSAGE AND ADMINISTRATION, and CLINICAL STUDIES sections).
The safety and effectiveness of UNASYN have not been established for pediatric patients for intra-abdominal infections.
Dosage forms
Philippines
- Powder for injection: 0 mg/250 mg, 1 g/500 mg, 1.5 g, 250 mg/125 mg, 500 mg/250 mg, 750 mg
- Powder for solution for injection: 1 g/500 mg, 500 mg/250 mg
- ) powder for injection: 500 mg/250 mg (750 mg
- Per vial powder for injection: 1 g/500 mg
- Powder for solution for i.m/i.v: 500 mg/250 mg
- Sterile powder for injection: 750 mg
Registered products in the Philippines
163 products registered with the Food and Drug Administration (FDA) Philippines list Ampicillin + Sulbactam as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products163
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
ActacilAmpicillin (as sodium) + Sulbactam (as sodium) | 500 mg/250 mg Powder for Injection (IM/IV)USP Type I Glass Vial (Box of 1’s) | Rx | Samjin Pharmaceutical Co., Ltd.Republic Of Korea | UniGlobal Group Marketing Corp.Importer: Medbridge, Inc. | DRP-3252-01 | Mar 3, 2031 | |
Aepisul 1.5Ampicillin (As Sodium) + Sulbactam (As Sodium) | 1g/500mg Powder For Injection (IM/IV)USP Type I Clear Glass Vial (Box of 1's) | Rx | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.China | Sahar International Trading, Inc. | DRP-3351-02 | Oct 25, 2027 | |
Aepisul 750Ampicillin (As Sodium) + Sulbactam (As Sodium) | 500 mg/250 mg Powder For Injection (IM/IV)USP Type I Clear Glass Vial x l's (Box of 1's) | Rx | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.China | Dynasty PharmaceuticalsImporter: Sahar International Trading, Inc. | DRP-3944-01 | Aug 31, 2027 | |
Amebactam-1.5Ampicillin (as sodium) + Sulbactam (as sodium) | 1 g/500 mg Powder for Injection (IM/IV)20 mL USP Type III clear and colorless glass vial with gray bromobutyl rubber stopper and aluminum seal with white flip-off cap + 10mL Sterile Water for Injection diluent in LDPE ampoule (Box of 1's) | Rx | Med Biopharma Pvt. Ltd.India | Amedesons Drug HouseImporter: Pors Pharma Trading | DRP-15054-03 | Aug 4, 2028 | |
Amebactam-750Ampicillin (as sodium) + Sulbactam (as sodium) | 500 mg/250 mg Powder for Injection (IM/IV)10 mL USP Type III clear and colorless glass vial with gray bromobutyl rubber stopper and aluminum seal with white flip-off cap + 10 mL Sterile Water for Injection diluent in LDPE ampoule (Box of 1's) | Rx | Med Biopharm Pvt. Ltd.India | Amedesons Drug HouseImporter: Pors Pharma Trading | DRP-14996-01 | Aug 4, 2028 | |
AmkotamAmpicillin (as sodium) + Sulbactam (as sodium) | 500 mg/250 mg Powder for Injection (IV/IM)5 mL USP Type I Clear Glass Vial per box | Rx | Swiss Parenterals LtdIndia | AMK Pharma International TradingImporter: Ambica International Corporation | DRP-6930-07 | Sep 30, 2027 | |
AmpicareAmpicillin (as sodium) + Sulbactam (as sodium) | 500 mg/250 mg Powder for Injection (I.M./I.V.)USP Type I Borosilicate Clear Transparent Glass Vial with Butyl Rubber Stopper Sealed with Aluminum Plastic Cap and Blue Flip-Off x 7 mL Box of 1’s in 10’s; USP Type I Borosilicate Clear Transparent Glass Vial with Butyl Rubber Stopper Sealed with Aluminum Plastic Cap and Blue Flip-Off x 7 mL Box of 10's | Rx | NORTH CHINA PHARMACEUTICAL CO., LTD.China | AGLOBAL CARE, INC. | DRP-8057 | Jul 10, 2028 | |
Ampihil 1.5Ampicillin (as sodium) + Sulbactam (as sodium) | 1 g/ 500 mg Powder for Injection (I.M./I.V.)10 mL clear Type I tubular glass vial with butyl rubber stopper and flip-off cap (Box of 1's and Box of 10's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Hillcross Prime, Inc.Importer: Sanimed Pharmaceuticals Inc. | DRP-10602-01 | Oct 22, 2031 | |
AmpimarAmpicillin (As Sodium) + Sulbactam (As Sodium) | 1g/500mg Powder For Injection (IM/IV)USP Type I Clear Glass Vial (Box of 1's) | Rx | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.China | Amson PharmaceuticalsImporter: Sahar International Trading, Inc. | DRP-3351-01 | Oct 25, 2027 | |
AmpimarAmpicillin (As Sodium) + Sulbactam (As Sodium) | 500mg/250mg Powder For Injection (IM/IV)USP Type I Clear Glass Vial x l's (Box of 1's) | Rx | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.China | Amson PharmaceuticalsImporter: Sahar International Trading, Inc. | DRP-3944-02 | Aug 31, 2027 | |
AmpimaxAmpicillin (as sodium) + Sulbactam (as sodium) | 1.5 g Powder for Injection (I.M./I.V.)20 mL USP Type I Glass Vial with Grey Butyl Rubber Closure with Leaf Green Aluminum Flip-off seal Box of 1’s | Rx | Unichem Laboratories Limited (Unit I)India | UNILAB, Inc.Importer: Ambica International Corporation | DRP-3649-01 | Dec 18, 2028 | |
AmpimaxAmpicillin (as sodium) + Sulbactam (as sodium) | 750 mg Powder for Injection (I.M./I.V.)10 mL USP Type I Glass Vial with Grey Butyl Rubber Closure with Burgundy Aluminum Flip-off seal Box of 1’s | Rx | Unichem Laboratories Ltd (Unit I)India | UNILAB, Inc.Importer: Ambica International Corporation | DRP-3648-01 | Dec 18, 2028 | |
AMPINEX PLUSAmpicillin (as Sodium) + Sulbactam (as Sodium) | 1g/500 mg Powder for Injection (I.M./1.V.)USP Type I Tubular Clear Glass Vial with blue Plastic flip-off x 10 mL Box of 1's | Rx | Reyoung Pharmaceutical Co., Ltd.China | NEXT CHEMICAL ENTERPRISES | DRP-9340 | Dec 27, 2028 | |
Ampinix -1.5Ampicillin (as sodium) + Sulbactam (as sodium) | 1 g/500 mg Powder for Injection (IM/IV)USP Type I Clear Glass Vial (Box of 1’s) | Rx | Yeluri Formulations Pvt. Ltd.India | Ranixx PharmaceuticalsImporter: Suhitas Pharmaceuticals Inc.Trader: Sherrington Pharmaceuticals Pvt. Ltd. | DRP-5009-05 | Dec 11, 2028 | |
Ampinix-750Ampicillin (as sodium) + Sulbactam (as sodium) | 500 mg/250 mg Powder for Injection (IM/IV)USP Type I Clear Glass Vial Box of 1’s | Rx | Yeluri Formulations Pvt. Ltd.India | Ranixx PharmaceuticalsImporter: Suhitas Pharmaceuticals Inc.Trader: Sherrington Pharmaceuticals Pvt. Ltd. | DRP-5007-04 | Dec 11, 2028 | |
AMPIRIXXAmpicillin (as sodium) + Sulbactam (as sodium) | 500 mg/250 mg Powder for Injection (IM/IV)12 mL USP Type II Colorless Glass Vial Individually Packed in a box (Box of 10's) | Rx | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Development Zone, Shijiazhuang, ChinaChina | BIO ERIXX PHARMA DISTRIBUTIONImporter: AMB HK Enterprises Inc. | DRP-5102-06 | Feb 6, 2032 | |
Ampisaphtam-15000Ampicillin (as sodium) + Sulbactam (as sodium) | 1 g/500 mg powder for Injection (IM/IV)10 mL-capacity USP Type I clear glass vial with grey bromo butyl rubber stopper and royal blue coloured flip off seal (Box of 1's and 10's) | Rx | Bueno Salud Care (India) Pvt. Ltd.India | Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt., Ltd. | DRP-15371 | Jun 28, 2029 | |
Ampisaphtam-750Ampicillin (as sodium) + Sulbactam (as sodium) | 500 mg/250 mg Powder for Injection (IM/IV)USP Type I clear glass vial with grey bromo butyl rubber stopper and royal blue coloured aluminum flip- off seal (Box of 1's and 10's) | Rx | Bueno Salud Care (India) Pvt. Ltd.India | Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt., Ltd. | DRP-15373 | Jun 28, 2029 | |
Ampistar SAmpicillin (as sodium) + Sulbactam (as sodium) | 1 g/500 mg Powder for Injection (I.V./I.M.)USP Type III clear glass vial closed with bromo butyl rubber stopper and sealed with blue flip off seal (Box of 10's) | Rx | Inject Care Parenterals Pvt. Ltd.India | Pharmastar Int'l Trading Corp. | DRP-14646 | Nov 14, 2028 | |
AmpisudenAmpicillin (as sodium) + Sulbactam (as sodium) | 500 mg/250 mg Powder for Injection (IM/IV)12 mL USP Type II Colorless Glass Vial Individually packed in a box (Box of 10’s) | Rx | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.China | Cyden Medicale Trading, Inc.Importer: AMB HK Enterprises, Inc. | DRP-5102-05 | Feb 8, 2031 | |
AmpisulifeAmpicillin (As Sodium) + Sulbactam (As Sodium) | 1 g/500 mg Powder for Injection (I.M./I.V.)USP Type I clear glass vial x 10 mL (net content) with grey bromobutyl rubber stopper, aluminum seal and flip-off cap (Box of 1’s + 5 mL clear glass ampoule diluent; Box of 10’s) | Rx | Anhil Parenteral Pvt. Ltd.India | Biophil Medical Equipment and Supplies Trading | DRP-18549 | Jul 29, 2031 | |
AmpisulmaxAmpicillin (as sodium) + Sulbactam (as sodium) | 1g / 500mg Powder for Injection (I.V. / I.M.)USP Type II Tubular Glass Vial with Butyl Rubber Stopper and Blue Flip-off Cap and Sterile Water for Injection as Diluent in USP Type I Clear and Colorless Glass Ampoule x 10mL (Box of 1 Vial + 1 Ampoule) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Dreamax Life Sciences IncorporatedImporter: Dreamax Incorporated | DRP-11209-02 | Feb 15, 2027 | |
AmpitamAmpicillin (as sodium) + Sulbactam (as sodium) | 500 mg/250 mg Powder for Injection (IM/IV)12 mL USP Type II Colorless Glass Vial individually packed in a box (Box of 10's) | Rx | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.China | Twostar Pharmaceutical TradingImporter: AMB HK Enterprises Inc. | DRP-5102 | Feb 8, 2031 | |
Ampix PlusAmpicillin (as sodium) + Sulbactam (as sodium) | 500 mg/250 mg Powder for Injection (IM/IV)USP Type I Glass Vial (Box of 1’s) | Rx | Samjin Pharmaceutical Co., Ltd.Republic Of Korea | Nutramedica Inc.Importer: Medbridge, Inc. | DRP-3252-02 | Mar 3, 2031 | |
Amsudime -1.5Ampicillin (as sodium) + Sulbactam (as sodium) | 1 g/500 mg Powder for Injection (IM/IV)USP Type I Clear Glass Vial (Box of 1’s) | Rx | Yeluri Formulations Pvt. Ltd.India | Pharmadyme Philippines, Inc.Importer: Suhitas Pharmaceuticals Inc.Trader: Sherrington Pharmaceuticals Pvt. Ltd. | DRP-5009-03 | Dec 11, 2028 | |
Amsudime-750Ampicillin (as sodium) + Sulbactam (as sodium) | 500 mg/250 mg Powder for Injection (IM/IV)USP Type I Clear Glass Vial (Box of 1’s) | Rx | Yeluri Formulations Pvt. Ltd.India | Pharmadyme Philippines, Inc.Importer: Suhitas Pharmaceuticals Inc.Trader: Sherrington Pharmaceuticals Pvt. Ltd. | DRP-5007-03 | Dec 11, 2028 | |
AmsulAmpicillin (as Sodium) + Sulbactam (as Sodium) | 1 g/500 mg Powder for Injection (IM/IV)USP Type I Clear Glass Vial (Box of 1's) | Rx | Swiss Parenterals Ltd.India | Endure Medical, Inc. | DR-XY46329 | May 4, 2028 | |
AmsulAmpicillin (as Sodium) + Sulbactam (as Sodium) | 1g / 500 mg Powder for Injection (IM/IV)USP Type I Clear Glass Vial (Box of 1's) | Rx | Swiss Parenterals Ltd.India | Endure Medical, Inc. | DRP-15941 | May 4, 2028 | |
AmsulAmpicillin (as Sodium) + Sulbactam (as Sodium) | 1g/500mg Powder for Injection (IM/IV)Clear Glass Vial with Rubber Stopper and Blue flip-off seal placed in plastic tray (Box of 10's) | Rx | Singapore Pharmawealth Lifesciences, Inc.Laguna | Endure Medical, Inc.Trader: Phil. Pharmawealth, Inc. | DRP-1556-03 | Nov 19, 2027 | |
AmsulAmpicillin (as Sodium) + Sulbactam (as Sodium) | 500 mg / 250 mg Powder for Injection (IM/IV)USP Type I Clear Glass Vial (Box of 1's) | Rx | Swiss Parenterals Ltd.India | Endure Medical, Inc. | DRP-15940 | May 4, 2028 | |
AmsulAmpicillin (as Sodium) + Sulbactam (as Sodium) | 500 mg/250 mg Powder for Injection (IM/IV)USP Type I Clear Glass Vial (Box of 1's) | Rx | Swiss Parenterals Ltd.India | Endure Medical, Inc. | DR-XY46330 | May 4, 2028 | |
AmsulAmpicillin (as Sodium) + Sulbactam (as Sodium) | 500mg / 250mg Powder for Injection (I.V./I.M.)Clear glass vial with rubber stopper and yellow flip-off seal placed in plastic tray (Box of 10's) | Rx | Singapore Pharmawealth Lifesciences, Inc.Laguna | Endure Medical, Inc.Trader: Phil. Pharmawealth, Inc. | DRP-2337-03 | Dec 14, 2029 | |
AmsulsynAmpicillin (As Sodium) + Sulbactam (As Sodium) | 500 mg/ 250 mg Powder For Injection (IV/IM)5 mL USP Type 1 Clear Glass Vial per box | Rx | Swiss Parenterals Ltd.India | Diafarm Inc.Importer: Ambica International Corporation | DRP-6930-12 | Apr 27, 2031 | |
AmsulvexAmpicillin (as Sodium) + Sulbactam (as Sodium) | 1 g/500 mg Powder for Injection (IM/IV)Type III Clear Glass Vial with Blue Flip-off Seal (Box of 1's and 10's) | Rx | NORTH CHINA PHARMACEUTICAL CO., LTDChina | SANNOVEX PHARMACEUTICAL DISTRIBUTOR | DRP-2578 | May 14, 2029 | |
AmsulvexAmpicillin (as Sodium) + Sulbactam (as Sodium) | 500 mg/250 mg Powder for Injection (IM/IV)Type III Clear Glass Vial with blue flip-off seal (Box of 1's and 10's) | Rx | NORTH CHINA PHARMACEUTICAL CO., LTDChina | SANNOVEX PHARMACEUTICAL DISTRIBUTOR | DRP-2575 | May 14, 2029 | |
AmsumedAmpicillin (as sodium) + Sulbactam (as sodium) | 1 g/ 500 mg Powder for Injection (I.M./I.V.)10 mL clear Type I tubular glass vial with butyl rubber stopper and flip-off cap (Box of 1's) and (Box of 10's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Sanimed Pharmaceuticals Inc. | DRP-10602 | Oct 22, 2036 | |
AmsumedAmpicillin (as sodium) + Sulbactam (as sodium) | 500 mg /250 mg Powder for Injection (I.M./I.V.)10 mL clear Type I tubular glass vial with butyl rubber stopper and flip-off cap (Box of 1's) and (Box of 10's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Sanimed Pharmaceuticals Inc. | DRP-10603 | Oct 22, 2036 | |
AmsutasAmpicillin (as sodium) + Sulbactam (as sodium) | 1 g/500 mg Powder for Injection (IM/IV)USP Type I Clear Glass Vial (Box of 1’s) | Rx | Yeluri Formulations Pvt. Ltd.India | Suhitas Pharmaceuticals Inc.Trader: Sherrington Pharmaceuticals Pvt. Ltd. | DRP-5009 | Dec 11, 2028 | |
AmsutasAmpicillin (as sodium) + Sulbactam (as sodium) | 500 mg/250 mg Powder for Injection (IM/IV)USP Type I Clear Glass Vial (Box of 1’s) | Rx | Yeluri Formulations Pvt. Ltd.India | Suhitas Pharmaceuticals Inc.Trader: Sherrington Pharmaceuticals Pvt. Ltd. | DRP-5007 | Dec 11, 2028 | |
AmtacilAmpicillin (as sodium) + Sulbactam (as sodium) | 1 g/500 mg Powder for Injection (IM/IV)10 mL-capacity USP Type II glass vial with butyl rubber stopper and flip-off cap (Box of 10's) | Rx | Reyoung Pharmaceutical Co., LtdChina | Dreamax Incorporated | DRP-15749 | Sep 10, 2029 | |
Amtacil-WFIAmpicillin (as sodium) + Sulbactam (as sodium) | 1 g/500 mg Powder for Injection (I.V./I.M.)USP Type II Tubular Glass Vial with Butyl Rubber Stopper and Blue Flip-off Cap and Sterile Water for Injection as Diluent in USP Type I Clear | Rx | Reyoung Pharmaceutical Co., Ltd.China | Dreamax Incorporated | DRP-11209 | Feb 15, 2027 | |
AnsulmaxAmpicillin (as sodium) + Sulbactam (as sodium) | 1g/500mg Powder for Injection (IV/IM)USP Type II Tubular Glass Vial with Butyl Rubber Stopper and Blue Flip-off Cap and Sterile Water for Injection as Diluent in USP Type I Clear and Colorless Glass Ampoule x 10 mL (Box of 1 Vial + 1 Ampoule) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Dreamax Life Sciences IncorporatedImporter: Dreamax Incorporated | DRP-11209-03 | Feb 15, 2027 | |
AnsulmedAmpicillin (as sodium) + Sulbactam (as sodium) | 1 g/ 500 mg Powder for Injection (I.V./I.M.)USP Type II Tubular Glass Vial with Butyl Rubber Stopper and Blue Flip-off Cap and Sterile Water for Injection as Diluent in USP Type I Clear and Colorless Glass Ampoule x 10mL (Box 1 Vial + 1 Ampoule) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Dreamax Life Sciences IncorporatedImporter: Dreamax Incorporated | DRP-11209-01 | Feb 15, 2027 | |
AsulbacAmpicillin (as sodium) + Sulbactam (as sodium) | 1g/ 500mg Powder for Injection (I.V./I.M.)20 mL-capacity USP Type III clear and colorless glass vial with grey butyl rubber stopper and aluminum seal with cream colored flip-off cap + 5 mL (net content) LDPE ampoule of Sterile Water for Injection as diluent in opaque white plastic tray (Box of 1's) | Rx | Akums Drugs & Pharmaceuticals Ltd.India | Hexagon Pharmaceuticals | DR-XY47597 | Dec 9, 2026 | |
BactacareAmpicillin (as sodium) + Sulbactam (as sodium) | 500 mg/250 mg Powder for Injection (IM/IV)12 mL USP Type II Colorless Glass Vial Individually Packed in a box (Box of 10's) | Rx | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.China | Msf Pharmaceutical ProductsImporter: AMB HK Enterprises Inc. | DRP-5102-03 | Feb 4, 2032 | |
BactacinAmpicillin(as sodium)+Sulbactam(as sodium) | 1g/500mg Powder for Injection(IM/IV)USP Type I Glass Vial x 10's Box of 10's | Rx | Shin Poong Pharmaceutical Co., Ltd.Korea | Phil Shinpoong Pharma, Inc. | DRP-5382 | Jul 10, 2029 | |
Bactacin 750Ampicillin (as Sodium) + Sulbactam (as Sodium) | 500 mg/250 mg Powder for Injection (IM/IV)USP Type I Glass Vial x 10's (Box of 10's) | Rx | Shin Poong Pharmaceutical Co., Ltd.Korea | Phil. Shin Poong Pharma, Inc. | DRP-5442 | May 31, 2027 | |
Bactalev 1.5Ampicillin (as sodium) + Sulbactam (as sodium) | 1 g / 500 mg Powder for Solution for Injection (I.M./I.V.)20 mL USP Type III clear glass vial closed with 20 mm grey bromo butyl rubber stopper and blue aluminum flip off - seal (Box of 1's and 10's) | Rx | Inject Care Parenterals Pvt. Ltd.India | HLM Pharmaceutical Inc.Importer: Orange Biotec Inc. | DRP-11727-01 | Apr 22, 2027 | |
Bactalev 1.5Ampicillin (as sodium) + Sulbactam (as sodium) | 1 g/500 mg Powder for Injection (IM/IV)USP Type I Clear Glass Vial (Box of 1’s) | Rx | Yeluri Formulations Pvt. Ltd.India | HLM Pharmaceutical Inc.Importer: Suhitas Pharmaceuticals Inc.Trader: Sherrington Pharmaceuticals Pvt. Ltd. | DRP-5009-06 | Dec 11, 2028 | |
Bactalev 750Ampicillin (as sodium) + Sulbactam (as sodium) | 500 mg / 250 mg Powder for Solution for Injection (I.M./I.V.)USP Type III Clear Glass Vial with Grey Butyl Rubber Stopper and Aluminum Flip-off Seal (Box of 1's and 10's) | Rx | Inject Care Parenterals Pvt. Ltd.India | HLM Pharmaceutical Inc.Importer: Orange Biotec Inc. | DRP-12470-01 | Aug 16, 2027 | |
Bactalev-750Ampicillin (as sodium) + Sulbactam (as sodium) | 500 mg/250 mg Powder for Injection (IM/IV)USP Type I Clear Glass Vial (Box of 1’s) | Rx | Yeluri Formulations Pvt. Ltd.India | HLM Pharmaceutical Inc.Importer: Suhitas Pharmaceuticals Inc.Trader: Sherrington Pharmaceuticals Pvt. Ltd. | DRP-5007-05 | Dec 11, 2028 | |
BactamedAmpicillin (as sodium) + Sulbactam (as sodium) | 1 g / 500 mg Powder for Injection (I.M./I.V.)10 mL Type II tubular glass vial with butyl rubber stopper with a flip off cap (Box of 1’s) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Medirich Pharma Distribution Corp.Importer: Aglobal Care, Inc. | DRP-11962-03 | May 24, 2027 | |
BactamedAmpicillin (As Sodium) + Sulbactam (As Sodium) | 500mg/250mg Powder For Injection (IV/IM)USP Type II glass vial x 10 mL sealed with butyl rubber stopper and aluminum flip-off cap (Box of 1’s) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Medirich Pharma Distribution Corp.Importer: Aglobal Care, Inc. | DRP-12252-04 | Jul 4, 2027 | |
BacticareAmpicillin (as sodium) + Sulbactam (as sodium) | 1 g/500 mg Powder for Injection (I.M./I.V.)Molded glass vial with butyl rubber stopper and aluminum-plastic cap (Box of 1’s) | Rx | North China Pharmaceutical Co., Ltd.China | Euro-Care Products Philippines | DRP-12026 | May 31, 2027 | |
BacticareAmpicillin (as sodium) + Sulbactam (as sodium) | 500 mg /250 mg Powder for Injection (I.M./I.V.)Molded glass vial with halogenated butyl rubber stopper and aluminum-plastic caps (Box of 1’s) | Rx | North China Pharmaceutical Co., Ltd.China | Euro-Care Products Philippines | DRP-12025 | May 31, 2027 | |
BacticonAmpicillin (as sodium) + Sulbactam (as sodium) | 1 g/ 500 mg Powder for Injection (I.M./I.V.)10 mL clear Type I tubular glass vial with butyl rubber stopper and flip-off cap (Box of 1's and 10's) | Rx | Reyoung Pharmaceutical Co., Ltd.Shandong Province China | D'Conner PharmaImporter: Sanimed Pharmaceuticals Inc. | DRP-10602-02 | Oct 22, 2031 | |
BactinextAmpicillin (as sodium) + Sulbactam (as sodium) | 1g / 500 mg Powder for Injection (I.V./I.M)USP Type II Tubular Glass Vial with Butyl Rubber Stopper and Flip-off Cap (Box of 10's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Diafarm Inc.Importer: Ambicare Pharmaceuticals Inc. | DRP-11465-01 | Mar 15, 2027 | |
BactinextAmpicillin (as sodium) + Sulbactam (as sodium) | 500 mg / 250 mg Powder for Injection (I.V./I.M)USP Type II Tubular Glass Vial with Butyl Rubber Stopper and Flip-off Cap (Box of 10's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Diafarm Inc.Importer: Ambicare Pharmaceuticals Inc. | DRP-11464-01 | Mar 15, 2027 | |
BactisulAmpicillin (as sodium) + Sulbactam (as sodium) | 1g / 500mg Powder for Injection (I.M/I.V.)20 mL USP Type II moulded glass vial with butyl rubber stopper and flip-off cap + 10 mL ampoule (Sterile Water for Injection as diluent) [Box of 1's] | Rx | Reyoung Pharmaceutical Co., Ltd.China | Reta DrugImporter: Medinova Pharmaceutical Inc. | DRP-11662-02 | Apr 7, 2027 | |
Bactropen PlusAmpicillin (as sodium) + Sulbactam (as sodium) | 1 g/ 500 mg Powder for Injection (I.M./I.V.)USP Type I Glass Vial (Box of 1’s) | Rx | Samjin Pharmaceutical Co., Ltd.Republic Of Korea | Medhaus Pharma, IncorporatedImporter: Medbridge, Inc. | DRP-5298-01 | Mar 3, 2031 | |
BaczillinAmpicillin (as sodium) + Sulbactam (as sodium) | 1 g/500 mg Powder for Injection (IM/IV)10 mL-capacity glass vial with butyl rubber stopper and aluminum flip-off seal (Box of 1's and 10's) | Rx | North China Pharmaceutical Co., Ltd.China | GPC Geo Pharma Corporation.Trader: Kwan Star Co., Ltd. | DRP-15490 | Jul 30, 2029 | |
BaczillinAmpicillin (as sodium) + Sulbactam (as sodium) | 500 mg/250 mg Powder for Injection (IM/IV)10 mL-capacity glass vial with butyl rubber stopper and aluminum flip-off seal (Box of 1's and 10's) | Rx | North China Pharmaceutical Co., Ltd.China | GPC Geo Pharma CorporationTrader: Kwan Star Co., Ltd. | DRP-15491 | Jul 30, 2029 | |
Ciltamin 1.5Ampicillin (as Sodium) + Sulbactam (as Sodium) | 1 g/ 500 mg Powder for Injection (I.M./I.V.)USP Type I glass vial with orange coloured flip-off seal (Box of 1’s) | Rx | SAMJIN PHARMACEUTICAL CO., LTD.Republic of Korea | NATRAPHARM, INC. | DR-XY39040 | Feb 10, 2029 | |
Ciltamin 750Ampicillin (as sodium) + Sulbactam (as sodium) | 500 mg/ 250 mg Powder for Injection (I.M./I.V.)USP Type I Glass Vial with Green Coloured Flip-off Seal (Box of 1’s) | Rx | SAMJIN PHARMACEUTICAL CO., LTD.Republic of Korea | NATRAPHARM, INC. | DR-XY38898 | Dec 28, 2028 | |
ClestramAmpicillin (as Sodium) + Sulbactam (as Sodium) | 500 mg/250 mg Powder for Injection (I.M./I.V.)USP Type III Glass Vial with rubber stopper and white flip-off seal (Box of 1 vial + 1 diluent) | Rx | ZAZEN PHARMA PVT. LTD.India | Medethix, Inc.Importer: I.E. Medica, Inc.Trader: Stratgen Healthcare Pvt. Ltd. | DRP-2607-03 | Nov 22, 2028 | |
DuobaclinAmpicillin (as sodium) + Sulbactam (as sodium) | 500 mg/250 mg Powder for Injection (IV/IM)5 mL USP Type I Clear Glass Vial per box | Rx | Swiss Parenterals Ltd.India | Euparex Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-6930-08 | Sep 29, 2030 | |
Dypisul 1.5Ampicillin (as sodium) + Sulbactam (as sodium) | 1G/500mg Powder for Injection (I.M./I.V.)10 mL-capacity USP Type II clear and colorless glass vial enclosed with butyl rubber stopper and aluminum seal with blue flip-off cap (Box of 10's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Dynasty Pharmaceuticals | DR-XY48827 | Jul 28, 2028 | |
Dypisul 750Ampicillin (as sodium) + Sulbactam (as sodium) | 500 mg / 250 mg Powder for Injection (IM/IV)10 mL- capacity USP Type II clear and colorless glass vial enclosed with butyl rubber stopper and aluminum seal with blue flip-off cap (Box of 10's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Dynasty Pharmaceuticals | DRP-15161 | Jul 28, 2028 | |
Dypisul 750Ampicillin (as sodium) + Sulbactam (as sodium) | 500mg/250mg Powder For Injection (IM/IV)10 mL-capacity USP Type II clear and colorless glass vial enclosed with butyl rubber stopper and aluminum seal with blue flip-off cap (Box of 10's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Dynasty Pharmaceuticals | DR-XY48826 | Jul 28, 2028 | |
EffebactamAmpicillin (as sodium) + Sulbactam ( as sodium) | 500mg/250mg Powder for Injection (I.M./I.V.)USP Type I Clear Glass Vial (Box of 1's) (Box of 1's) | Rx | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.China | Sahar Pharmaceuticals DistributionImporter: Sahar International Trading, Inc. | DRP-3944-03 | Dec 10, 2030 | |
Firbactam-1.5Ampicillin (as sodium) + Sulbactam (as sodium) | 1g/ 500mg Powder for Injection (IM/IV)20 mL USP Type III clear and colorless glass vial with gray bromobutyl rubber stopper and aluminum seal with white flip-off cap + 10 mL Sterile Water for Injection diluent in LDPE ampoule (Box of 1's) | Rx | Med Biopharm Pvt. Ltd.India | Medarruz Pharmaceutical Philippines IncImporter: Pors Pharma Trading | DRP-15054-01 | Aug 4, 2028 | |
GensynAmpicillin (Sodium) + Sulbactam (Sodium) | 1 g/500 mg Powder for Injection (I.M./I.V)20 mL USP Type II Moulded Glass Vial with Butyl Rubber Stopper and Flip-off Cap + 10 mL Ampoule (Sterile Water for Injection as Diluent) [Box of 1's] | Rx | Reyoung Pharmaceutical Co. Ltd.China | GA2 Pharmaceutical Inc.Importer: Medinova Pharmaceutical Inc. | DRP-11662-01 | Apr 27, 2027 | |
GeobactamAmpicillin (as sodium) + Sulbactam (as sodium) | 500 mg/250 mg Powder for Injection (IM/IV)USP Type I Clear Glass Vial (Box of 1’s) | Rx | Yeluri Formulations Pvt. Ltd.India | GPC Geo Pharma CorporationImporter: Suhitas Pharmaceuticals Inc.Trader: Sherrington Pharmaceuticals Pvt. Ltd. | DRP-5007-02 | Dec 11, 2028 | |
Geobactam -1.5Ampicillin (as sodium) + Sulbactam (as sodium) | 1 g/500 mg Powder for Injection (IM/IV)USP Type I Clear Glass Vial (Box of 1’s) | Rx | Yeluri Formulations Pvt. Ltd.India | GPC Geo Pharma CorporationImporter: Suhitas Pharmaceuticals Inc.Trader: Sherrington Pharmaceuticals Pvt. Ltd. | DRP-5009-02 | Dec 11, 2028 | |
Geobactam 1.5Ampicillin (as sodium) + Sulbactam (as sodium) | 1 g/500 mg Powder for Solution for Injection (I.M./I.V.)20 mL USP Type III clear glass vial closed with 20 mm grey bromo butyl rubber stopper and blue aluminum flip-off seal (Box of 1's) | Rx | Inject Care Parenterals Pvt. Ltd.India | GPC Geo Pharma CorporationImporter: Orange Biotec Inc. | DRP-11727-02 | Apr 22, 2027 | |
GravitamAmpicillin (as sodium) + Sulbactam (as sodium) | 1 g/500 mg Powder for Injection (IM/IV)USP Type 1 Clear Glass Vial (Box of 1’s) | Rx | Yeluri Formulations Pvt. Ltd.India | Ellebasy Medicale TradingImporter: Suhitas Pharmaceuticals Inc.Trader: Sherrington Pharmaceuticals Pvt. Ltd. | DRP-5009-01 | Dec 11, 2028 | |
GravitamAmpicillin (as sodium) + Sulbactam (as sodium) | 500 mg/250 mg Powder for Injection (IM/IV)USP Type I Clear Glass Vial (Box of 1’s) | Rx | Yeluri Formulations Pvt. Ltd.India | Ellebasy Medicale TradingImporter: Suhitas Pharmaceuticals Inc.Trader: Sherrington Pharmaceuticals Pvt. Ltd. | DRP-5007-01 | Dec 11, 2028 | |
HAITAMAmpicillin (as Sodium) + Sulbactam (as Sodium) | 1 g/500 mg Powder for Injection (IM/IV)USP Type I Tubular Clear Glass Vial with Blue Plastic Flip-off x 10 mL (Box of 1's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | GREENCORE PHARMA INC.Importer: NEXT CHEMICAL ENTERPRISES | DRP-9340-02 | Dec 27, 2028 | |
HaitamAmpicillin (as Sodium) + Sulbactam (as Sodium) | 500mg/250 mg Powder for Injection (I.M./I.V.)10 mL USP Type I Clear Colorless Glass Vial with Butyl Rubber Stopper and Aluminum Crimp with Blue Plastic Flip-Off Cap (Box of 1's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Dynasty PharmaceuticalsImporter: Next Chemical Enterprises | DRP-9341-03 | Mar 11, 2029 | |
I-Bactam-1.5Ampicillin (as sodium) + Sulbactam (as sodium) | 1g/500 mg Powder for Injection (IM/IV)20 mL USP Type III clear and colorless glass vial with gray bromobutyl rubber stopper and aluminum seal with white flip-off cap + 10 mL Sterile Water for Injection diluent in LDPE ampoule (Box of 1's) | Rx | Med Biopharm Pvt. Ltd.India | Fier Pharma Trading Inc.Importer: Pors Pharma Trading | DRP-15054-02 | Aug 4, 2028 | |
Incillin Plus 1500Ampicillin (As Sodium) + Sulbactam (As Sodium) | 1 g/ 500 mg Powder For Injection (I.M./I.V.)20 mL-capacity USP Type III clear glass vial with. bromobutyl rubber stopper and aluminum seal with blue flip-off cap (Box of 1's) | Rx | Injectcare Parenterals Pvt LtdIndia | Aglobal Care, Inc.Trader: Antila Lifesciences Pvt. Ltd. | DRP-14761 | Dec 22, 2028 | |
Liferzin PlusAmpicillin (as sodium) + Sulbactam (as sodium) | 500 mg/250 mg (750 mg) Powder For Injection (IM/IV)Type II Clear glass vial x 10 mL (Box of 1's and 10's) | Rx | Reyoung Pharmaceuticals Co., Ltd.China | Philgen Pharmaceuticals Inc. | DRP-18365 | Jun 22, 2031 | |
LinsulAmpicillin (as sodium) + Sulbactam (as sodium) | 1 g/ 500 mg Powder for Injection (I.M./I.V.)USP Type I Glass Vial (Box of 1’s) | Rx | Samjin Pharmaceutical Co., Ltd.Republic of Korea | Medbridge, Inc. | DRP-5298 | Mar 3, 2031 | |
LinsulAmpicillin (as sodium) + Sulbactam (as sodium) | 500 mg/ 250 mg Powder for Injection (I.M./I.V.)USP Type I Glass Vial (Box of 1’s) | Rx | Samjin Pharmaceutical Co., Ltd.Republic of Korea | Medbridge, Inc. | DRP-3252 | Mar 3, 2031 | |
LintamAmpicillin (As Sodium) + Sulbactam(As Sodium) | 1 g/500 mg Powder For Solution For Injection (I.M/I.V.)20 mL USP Type III clear glass vial closed with 20 mm grey bromo butyl rubber stopper and blue aluminum flip off-seal (Box of 1's and 10's) | Rx | Inject Care Parenterals Pvt. Ltd.India | Suhitas Pharmaceuticals Inc. | DRP-11727 | Apr 22, 2027 | |
LintamAmpicillin (As Sodium) + Sulbactam(As Sodium) | 500 mg/ 250 mg Powder for Injection (I.V./I.M.)USP Type III Clear Glass Vial with Grey Butyl Rubber Stopper and Aluminum Flip-off Seal (Box of 10's) | Rx | Inject Care Parenterals Pvt. Ltd.India | Suhitas Pharmaceuticals Inc. | DRP-12470 | Aug 16, 2027 | |
MiasynAmpicillin (As Sodium) + Sulbactam (As Sodium) | 1g/500mg Powder For Injection (IM/IV)USP Type I Clear Glass Vial (Box of 1's) | Rx | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.China | Sahar International Trading, Inc. | DRP-3351 | Oct 25, 2027 | |
MiasynAmpicillin (As Sodium) + Sulbactam (As Sodium) | 500mg/250mg Powder For Injection (IM/IV)USP Type I clear glass vial (Box of 1's) | Rx | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.China | Sahar International Trading, Inc. | DRP-3944 | Aug 31, 2027 | |
NoneAmpicillin (as sodium) + Sulbactam (as sodium) | 1 g / 500 mg Powder for Injection (I.V./I.M)USP Type II Tubular Glass Vial with Butyl Rubber Stopper and Flip-off Cap (Box of 10's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Reta DrugImporter: Ambicare Pharmaceuticals Inc. | DRP-11465-03 | Mar 15, 2027 | |
NoneAmpicillin (as Sodium) + Sulbactam (as sodium) | 1 g /500 mg Powder for Injection (I.M./I.V.)10 mL Type II tubular glass vial with butyl rubber stopper with a flip off cap (Box of 1's) | Rx | Reyoung PharmaceuticalChina | Ritemed Phils., Inc.Importer: Aglobal Care, Inc. | DRP-11962-02 | Jul 4, 2027 | |
NoneAmpicillin (as sodium) + Sulbactam (as sodium) | 1 g/500 mg Powder for Injection (IM/IV)USP Type I Glass Vial x 10’s (Box of 10’s) | Rx | Shin Poong Pharmaceutical Co., Ltd.Republic of Korea | Ritemed Phils., Inc.Importer: Phil Shin Poong Pharma, Inc. | DRP-5382-03 | Jul 10, 2029 | |
NoneAmpicillin (as sodium) + Sulbactam (as sodium) | 1.5 g Powder for Injection (I.M./I.V.)20 mL USP Type I Glass Vial with Grey Butyl Rubber Closure with Leaf Green Aluminum Flip-off seal Box of 1’s | Rx | Unichem Laboratories Limited (Unit I)India | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-3649-02 | Dec 18, 2028 | |
NoneAmpicillin (as sodium) + Sulbactam (as sodium) | 500 mg / 250 mg Powder for Injection (IM/IV)USP Type I Glass Vial x 10’s (Box of 10’s) | Rx | Shin Poong Pharmaceutical Co., Ltd.Republic of Korea | Medicos Bio-Life Sciences, Inc.Importer: Phil. Shin Poong Pharma, Inc. | DRP-5442-04 | May 31, 2027 | |
NoneAmpicillin (as sodium) + Sulbactam (as sodium) | 500 mg/ 250 mg Powder for Injection (I.M./I.V.)USP Type I clear Glass Vial (Box of 1’s) | Rx | Unichem Laboratories Limited (Unit I)India | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International Corporation | DRP-5132-01 | Feb 13, 2029 | |
NoneAmpicillin (as sodium) + Sulbactam (as sodium) | 500 mg/250 mg Powder for Injection (I.V./I.M)USP Type II Tubular Glass Vial with Butyl Rubber Stopper and Flip-off Cap (Box of 10's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Reta DrugImporter: Ambicare Pharmaceuticals Inc. | DRP-11464-02 | Mar 15, 2027 | |
NoneAmpicillin (as Sodium) + Sulbactam (as sodium) | 500 mg/250 mg Powder for Injection (IV/IM)USP Type II glass vial x 10 mL sealed with butyl rubber stopper and aluminum flip-off cap (Box of 1's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Ritemed Phils., Inc.Importer: Aglobal Care, Inc. | DRP-12252-03 | Jul 4, 2027 | |
NovacAmpicillin (as sodium) + Sulbactam (as sodium) | 1 g/500 mg Powder for Injection (I.M./I.V.)20 mL USP Type II moulded glass vial with butyl rubber stopper and flip-off cap + 10 mL ampoule (Sterile Water for Injection as diluent) [Box of 1's] | Rx | Reyoung Pharmaceutical Co., Ltd.China | Medinova Pharmaceutical Inc. | DRP-11662 | Apr 7, 2027 | |
PhamsulAmpicillin (as sodium) + Sulbactam (as sodium) | 500 mg/250 mg Powder for Injection (IM/IV)USP Type III Glass Vial with rubber stopper and white flip-off seal (Box of I vial + 1 diluent) | Rx | Zazen Pharma Pvt. Ltd.India | I.E. Medica, Inc.Trader: Stratgen Healthcare Pvt. Ltd. | DRP-2607 | Nov 22, 2028 | |
PillsulbacAmpicillin (as sodium) + Sulbactam (as sodium) | 1 g/500 mg Powder for Injection (I.V/I.M)USP Type II Tubular Glass Vial with Butyl Rubber Stopper and Flip-off Cap (Box of 10’s) | Rx | Reyoung Pharmaceutical Co., Ltd.China | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambicare Pharmaceuticals Inc. | DRP-11465-04 | Mar 15, 2027 | |
PillsulbacAmpicillin (as sodium) + Sulbactam (as sodium) | 500 mg/250 mg Powder for Injection (I.V./I.M.)USP Type II Tubular Glass Vial with Butyl Rubber Stopper and Flip-off Cap (Box of 10’s) | Rx | Reyoung Pharmaceutical Co., Ltd.China | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambicare Pharmaceuticals Inc. | DRP-11464-03 | Mar 15, 2032 | |
Porbact-1.5Ampicillin (as sodium) + Sulbactam (as sodium) | 1 g / 500 mg Powder for Injection (IM/IV)20 mL USP Type III clear and colorless glass vial with gray bromobutyl rubber stopper and aluminum seal with white flip-off cap + 10 mL Sterile Water for Injection diluent in LDPE ampoule (Box of 1's) | Rx | Med Biopharm Pvt. Ltd.India | Pors Pharma Trading | DRP15054 | Aug 4, 2028 | |
Porbact-1.5Ampicillin (as sodium) + Sulbactam (as sodium) | 1 g/500 mg Powder for Injection (IM/IV)FBA 20 mL USP Type III clear and colorless glass vial with gray bromobutyl rubber stopper and aluminum seal with white flip-off cap + 10 mL Sterile Water for Injection diluent in LDPE ampoule (Box of 1's) | Rx | Med Biopharm Pvt. Ltd.India | Pors Pharma Trading | DR-XY48837 | Aug 4, 2028 | |
Porbact-750Ampicillin (as sodium) + Sulbactam (as sodium) | 500 mg / 250 mg Powder for Injection (IM/IV)10 mL USP Type III clear and colorless glass vial with gray bromobutyl rubber stopper and aluminum seal with white flip-off cap + 10 mL Sterile Water for Injection diluent in LDPE ampoule (Box of 1's) | Rx | Med Biopharm Pvt. Ltd.India | Pors Pharma Trading | DRP-14996 | Aug 4, 2028 | |
Porbact-750Ampicillin (as sodium) + Sulbactam (as sodium) | 500 mg/250 Powder for Injection (IM/IV)10 mL USP Type III clear and colorless glass vial with gray bromobutyl rubber stopper and aluminum seal with white flip-off cap + 10 mL Sterile Water for Injection diluent in LDPE ampoule (Box of 1's) | Rx | Med Biopharm Pvt. Ltd.India | Pors Pharma Trading | DR-XY48838 | Aug 4, 2028 | |
PrimucitamAmpicillin (as sodium) + Sulbactam (as sodium) | 1.5 g Powder for Injection (I.M./I.V.)20 mL USP Type I Glass Vial with Grey Butyl Rubber Closure with Leaf Green Aluminum Flip-off Seal (Box of 1’s) | Rx | Unichem Laboratories Limited (Unit I)India | AGB Pharmaceutical Trading and Consultancy Corp.Importer: Ambica International Corporation | DRP-3649-03 | Dec 18, 2028 | |
RAVITAMAmpicillin (as Sodium) + Sulbactam (as Sodium) | 1g/500 mg Powder for Injection (I.M./1.V.)USP Type I Tubular Clear Glass Vial with blue Plastic flip-off x 10 mL Box of 1's | Rx | Reyoung Pharmaceutical Co., Ltd.China | TRIPLE TACT IMPORT & EXPORT CORP.Importer: NEXT CHEMICAL ENTERPRISES | DRP-9340-01 | Dec 27, 2028 | |
Retaback-750Ampicillin (as sodium) + Sulbactam (as sodium) | 500 mg / 250 mg Powder for Injection (IV/IM)USP Type II Glass Vial x 10 mL sealed with butyl rubber stopper and aluminum flip-off cap (Box of 1's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Reta DrugImporter: Aglobal Care, Inc. | DRP-12252-01 | Jul 4, 2027 | |
Retabacx-1500Ampicillin (as Sodium) + Sulbactam (as Sodium) | 1 g/500 mg Powder for Injection (I.M./I.V.)10 mL Type II Tubular glass vial with butyl rubber stopper with a flip off cap (Box of 1's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Reta DrugImporter: Aglobal Care, Inc. | DRP-11962-01 | May 24, 2027 | |
RetasulAmpicillin (as sodium) + Sulbactam (as sodium) | 500 mg/250 mg Powder for Injection (IM/IV) | Rx | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.China | AMB HK Enterprises Inc. | DRP-8955-01 | Feb 11, 2031 | |
RiampisulAmpicillin (as sodium) + Sulbactam (as sodium) | 500 mg/ 250 mg Powder for Injection (I.M./I.V.)USP Type I clear colorless glass vial with grey butyl rubber stopper and aluminum cap with blue flip-off seal x 10 mL (Box of 1's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Champion Biotech and Pharma Corporation | DR-XY34335 | Mar 7, 2028 | |
RONPIBACAmpicillin (as sodium) + Sulbactam (as sodium) | 500 mg/250 mg Powder for Injection (IM/IV)12 mL USP Type II Colorless Glass Vial Individually Packed in a box (Box of 10's) | Rx | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.China | Medhart Pharma Inc.Importer: AMB HK Enterprises Inc. | DRP-5102-01 | Feb 4, 2032 | |
Sacriva-750Ampicillin (as sodium) + Sulbactam (as sodium) | 500 mg/250 mg Powder for Injection (IM/IV)12 mL USP Type II Colorless Glass Vial in a box (Box of 10’S) | Rx | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.China | PhilRx Pharma Inc.Importer: AMB HK Enterprises Inc. | DRP-5102-04 | Dec 13, 2031 | |
SambactamAmpicillin (as Sodium) + Sulbactam (as Sodium) | 1 g/500 mg Powder for Injection (IM/IV)USP Type I Clear Glass Vial with Rubber Plug and Sealed with Aluminum Seal (Box of 10's) | Rx | Singapore Pharmawealth Lifesciences, Inc.Philippines | — | DR-XY45448 | Jun 13, 2031 | |
SambactamAmpicillin (as sodium) + Sulbactam (as sodium) | 50 0mg/250 mg Powder for Injection (IM/IV)USP Type I clear glass vial sealed with rubber plug and aluminum seal (Box of 10's) | Rx | Singapore Pharmawealth Lifesciences, Inc.Philippines | — | DR-XY46618 (FOR EXPORT ONLY) | Jun 20, 2029 | |
SilgramAmpicillin (as sodium) + Sulbactam (as sodium) | 1 g/500 mg Powder for Injection (I.M./I.V.)Type III Clear Glass Vial with Rubber stopper and Aluminum Seal Box of 1's | Rx | YSS Laboratories Co., Inc.Philippines | Trader: The Cathay Drug Co., Inc. | DR-XY36108 | Jun 30, 2029 | |
SilgramAmpicillin (As Sodium) + Sulbactam (As Sodium) | 250 mg / 125 mg Powder For Injection (IM/IV)1 Clear Glass Vial with secondary box | Rx | YSS Laboratories Co. Inc.Philippines | Trader: The Cathay Drug Company Inc. | DR-XY30362 | Nov 25, 2026 | |
SilgramAmpicillin (As Sodium) + Sulbactam (As Sodium) | 500 mg / 250 mg Powder For Injection (IM/IV)Type III Clear Glass Vial with Rubber Stopper and Gold Aluminum Seal | Rx | YSS Laboratories Co., Inc.Philippines | Trader: The Cathay Drug Company Inc. | DR-XY30361 | Nov 25, 2026 | |
SitampexAmpicillin (as sodium) + Sulbactam (as sodium) + Sulbactam (as sodium) | 1 g/500 mg Powder for Injection (I.M./I.V.)USP Type II glass tubular vial with butyl rubber stopper and aluminum-cap (Box of 1's) | Rx | Reyoung Pharmaceutical Co., LTD.China | Sahar International Trading Inc. | DR-XY49230 | Sep 25, 2029 | |
SporasulAmpicillin (as sodium) + Sulbactam (as sodium) | 1 g/500 mg Powder for Injection (I.M./I.V.)Type I transparent colorless glass vial with bromobutyl elastic rubber stopper of aluminum flip off cap covered with polypropylene plastic cap + Type I colorless glass ampoule x 5 mL (net content as diluent - Sterile Water for Injection) (Box of 1 vial + 1 ampoule) | Rx | Egyptian International Pharmaceutical Industries Co. (EIPICO)Egypt | Ambica International Corporation | DRP-12175 | Jun 24, 2032 | |
SporasulAmpicillin (as sodium) + Sulbactam (as sodium) | 500 mg / 250 mg Powder For Solution For I.M/I.VPh Eur Type I colorless glass vial + 2 mL water for injection (diluent) | Rx | Egyptian International Pharmaceutical Industries Co. (EIPICO)Egypt | Ambica International Corporation | DRP-12176 | Jun 24, 2027 | |
SulbacinAmpicillin (as Sodium) + Sulbactam (as Sodium) | 1g/500 mg Powder for Injection (IM/IV)Clear Glass vial with rubber stopper and blue flip-off seal placed in plastic tray (Box of 10's) | Rx | Singapore Pharmawealth Lifesciences, Inc.Philippines | — | DRP-1556 | Nov 19, 2027 | |
SulbacinAmpicillin (as Sodium) + Sulbactam (as Sodium) | 250 mg / 125 mg Powder for Injection (I.V./I.M.)USP Type I clear glass vial with green flip-off seal (Box of 1's and 10's) | Rx | Singapore Pharmawealth Lifesciences, Inc.Philippines | — | DR-XY30393 | Dec 14, 2029 | |
SulbacinAmpicillin (as Sodium) + Sulbactam (as Sodium) | 500 mg / 250 mg Powder for Injection (I.V./I.M.)Clear glass vial with rubber stopper and yellow flip-off seal placed in plastic tray (Box of 10's) | Rx | Singapore Pharmawealth Lifesciences, Inc.Philippines | — | DRP-2337 | Dec 14, 2029 | |
Sulbacin 0.75Ampicillin (as sodium) + Sulbactam (as sodium) | 500 mg/ 250 mg Powder for Injection (I.M./I.V.)USP Type I clear Glass Vial (Box of 1’s) | Rx | Unichem Laboratories Limited (Unit I)India | Jalmed Pharma Inc.Importer: Ambica International Corporation | DRP-5132 | Feb 13, 2029 | |
Sulbacin 1.5Ampicillin (as sodium) + Sulbactam (as sodium) | 1 g/ 500 mg Powder for Injection (I.M./I.V.)USP Type I clear Glass Vial Box of 1’s | Rx | Unichem Laboratories LimitedIndia | Ambica International Corporation | DRP-5079 | Feb 11, 2029 | |
SulbaclinAmpicillin (as sodium) + Sulbactam (as sodium) | 1 g/500 mg Powder for Injection (IM/IV)USP Type I Clear Colorless Glass Vial + USP Type I Clear Colorless Glass Ampoule x 10 mL (Diluent) (Box of 1's) | Rx | Kwality Pharmaceuticals LimitedIndia | Clinbaxy International, Inc | DR-XY42178 | Jun 28, 2028 | |
SulbactizinAmpicillin (as sodium) + Sulbactam (as sodium) | 1 g/ 500 mg Powder for Injection (I.V./I.M.) | Rx | Reyoung Pharmaceutical Co. Ltd. | Basic Pharmaceutical CorporationImporter: Ambicare Pharmaceuticals Inc. | DRP-11465-2 | Mar 15, 2027 | |
SulbactomaxAmpicillin (As Sodium) + Sulbactam (As Sodium) | 1 g/500 mg Powder for Solution for Injection (IM/IV)USP Type I Clear Glass Vial With Gray Butyl Rubber Stopper and White Aluminum Flip-off Seal (Box of 1's) | Rx | MAAN PHARMACEUTICALS LTDIndia | LABMATE PHARMA INCImporter: STANGEN PHARMACEUTICALS PHILIPPINES INC | DR-XY45073 | Feb 22, 2029 | |
SulbaxenAmpicillin (as sodium) + Sulbactam (as sodium) | 1 g/500 mg Powder for Injection (IM/IV)20 mL USP Type III colorless glass vial with grey butyl rubber stopper and aluminium seal with red colored flip-off cap (Box of 1's) | Rx | Uni Medicolabs Inc.India | Greencore Pharma Inc. | DRP-15561 | Aug 14, 2029 | |
SulbaxenAmpicillin (as sodium) + Sulbactam (as sodium) | 500 mg/250 mg Powder for Injection (IM/IV)10 mL USP Type III colorless glass vial with grey butyl rubber stopper and aluminium seal with golden colored flip-off cap (Box of 1's) | Rx | Uni Medicolabs Inc.India | Greencore Pharma Inc. | DRP-15562 | Aug 14, 2029 | |
Sulpi-1500Ampicillin (as sodium) + Sulbactam (as sodium) | 1 g/500 mg Powder for Injection (I.M./I.V.)10 mL Type II tubular glass vial with butyl rubber stopper with a flip off cap (Box of l’s) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Aglobal Care, Inc. | DRP-11962 | May 24, 2027 | |
Sulpi-750Ampicillin (As Sodium) + Sulbactam (As Sodium) | 500mg/250mg Powder For Injection (IV/IM)USP Type II glass vial x 10 mL sealed with butyl rubber stopper and aluminum flip-off cap (Box of 1’s) | Rx | Reyoung Pharmaceutical Co., Ltd.China | AGlobal Care, Inc.Importer: Aglobal Care, Inc. | DRP-12252 | Jul 4, 2027 | |
Sulpisave-750Ampicillin (as Sodium) + Sulbactam (as Sodium) | 500mg/250mg Powder for injection (IV/IM)USP Type II glass vial x 10 mL sealed with butyl rubber stopper and aluminum flip-off cap (Box of 1's) | Rx | REYOUNG PHARMACEUTICAL CO., LTD.China | SAVELINK PHARMA AND TRADING CO.Importer: AGLOBAL CARE, INC. | DRP-12252-02 | Jul 4, 2027 | |
SultacillinAmpicillin (as Sodium) + Sulbactam (as Sodium) | 1 g/500 mg powder for injection (IM/IV)Clear and colorless glass vial with green flip-off seal with logo (Box of 10's) | Rx | Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd.China | PharmAsia-Cuvest Incorporated | DR-XY30397 | Dec 14, 2029 | |
SultacillinAmpicillin (as sodium) + Sulbactam (as sodium) | 500 mg/250 mg powder for injection (IM/IV)Clear and colorless glass vial with green flip-off seal with logo (Box of 10's) | Rx | Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd.China | PHARMASIA-CUVEST INCORPORATED | DR-XY30396 | Dec 14, 2029 | |
SulvacilAmpicillin (as sodium) + Sulbactam (as sodium) | 1 g/500 mg Powder for Injection (IM/IV)USP Type I Glass Vial x 10’s (Box of 10’s) | Rx | Shin Poong Pharmaceutical Co., Ltd.Republic of Korea | Elin Pharmaceuticals, Inc.Importer: Phil Shin Poong Pharma, Inc. | DRP-5382-02 | Jul 10, 2029 | |
SulvacilAmpicillin (as sodium) + Sulbactam (as sodium) | 500 mg/250 mg Powder for Injection (IM/IV)USP Type I Glass Vial x 10's (Box of 10's) | Rx | Shin Poong Pharmaceutical Co., Ltd.Korea | Elin Pharmaceuticals, Inc.Importer: Phil. Shin Poong Pharma, Inc. | DRP-5442-02 | May 31, 2027 | |
Surpitam-1.5Ampicillin (as sodium) + Sulbactam (as sodium) | 1 g/500 Powder for Injection (I.M./I.V.)10 mL-capacity USP Type II clear and colorless glass vial with butyl rubber stopper and aluminum seal with blue flip-off cap in a plastic tray (Box of 10's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Pharma-Surrey International, Inc. | DRP-14263 | Aug 4, 2028 | |
Surpitam-750Ampicillin (as sodium) + Sulbactam (as sodium) | 500mg/250mg Powder for Injection (I.M./I.V.)10mL - capacity USP Type II clear and colorless glass vial with butyl rubber stopper and aluminum seal with blue flip-off cap in a plastic tray (Box of 10's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Pharma-Surrey International, Inc. | DRP-14262 | Aug 4, 2028 | |
SybactamAmpicillin (as Sodium) + Sulbactam (as Sodium) | 500 mg / 250 mg Powder for Injection (IV/IM) | Rx | BIORX PHARMA LABS LLP | — | DRP-6930-11 | Nov 25, 2026 | |
SynthopenAmpicillin (as sodium) + Sulbactam (as sodium) | 1.5 g Powder for Injection (IM/IV)20 mL USP Type I Glass Vial with Grey Butyl Rubber Closure with Leaf Green Aluminum Flip-off seal (Box of 1’s) | Rx | Unichem Laboratories Limited (Unit I)India | Ambica International Corporation | DRP-3649 | Dec 18, 2028 | |
SynthopenAmpicillin (as sodium) + Sulbactam (as sodium) | 750 mg Powder for Injection (I.M./I.V.)10 mL USP Type I Glass Vial with Grey Butyl Rubber Closure with Burgundy Aluminum Flip-off seal (Box of 1’s) | Rx | Unichem Laboratories Limited (Unit I)India | Oro Sinai Pharma & General Merchandise, Inc.Importer: Ambica International Corporation | DRP-3648 | Dec 18, 2028 | |
UnacilynAmpicillin (as sodium) + Sulbactam (as sodium) | 1 g/500 mg Powder for Injection (IM/IV)USP Type III Clear Colorless Glass Vial Sealed with Grey BromoButyl Rubber Stopper and Flip-off Seal x 20 mL (Box of l's) | Rx | Karnataka Antibiotics & Pharma Ltd.India | Jackson Pharmaceuticals Inc. | DR-XY47595 | Dec 9, 2026 | |
UnacilynAmpicillin (As Sodium) + Sulbactam (As Sodium) | 750 mg Sterile Powder For Injection10cc USP type III glass vials with 20mm grey bromo buytyl rubber stoppers and sealed in blue flip off seals (Box of 1's) | Rx | KARNATAKA ANTIBIOTICS & PHARMA LTD.India | JACKSON PHARMACEUTICALS INC. | DR-XY46453 | Nov 14, 2028 | |
UNAMAXAmpicillin (as sodium) + Sulbactam (as sodium) | 1 g/500 mg Powder for Injection(IM/IV)USP Type I Glass Vial x 10’s (Box of 10’s) | Rx | Shin Poong Pharmaceutical Co., Ltd.Republic of Korea | MAXIPHARM CO., LTD.Importer: PHIL SHINPOONG PHARMA, INC. | DRP-5382-01 | Jul 10, 2029 | |
Unamax-750Ampicillin (as sodium) + Sulbactam (as sodium) | 500 mg/250 mg Powder for Injection (IM/IV)USP Type I Glass Vial x 10's (Box f 10's) | Rx | Shin Poong Pharmaceutical Co., LtdKorea | Maxipharm Co., Ltd.Importer: Phil. Shin Poong Pharma, Inc. | DRP-5442-01 | May 31, 2027 | |
UnasynAmpicillin (as Sodium) + Sulbactam (as Sodium) | 1 g/500 mg per vial Powder for Injection (I.M./I/V.)Clear Glass Vial with Grey rubber stopper with Blue flip-off (Box of 1's) | Rx | Haupt Pharma Latina S.r.l.Italy | Importer: Pfizer, Inc. | DRP-1901 | Feb 9, 2031 | |
UnathixAmpicillin Sodium + Sulbactam Sodium | 500 mg/250 mg Powder For Injection (Im/Iv)USP Type III clear glass vial with white flip-off seal | Rx | — | — | DRP-2607-01 | Nov 22, 2028 | |
UnatreneAmpicillin (as sodium) + Sulbactam (as sodium) | 1g/500mg Powder for Injection(IM/IV)USP Type I Glass Vial x 10’s (Box of 10’s) | Rx | Shin Poong Pharmaceutical Co., Ltd.Republic of Korea | Aisec Farma CorporationImporter: Phil Shinpoong Pharma, Inc. | DRP-5382-04 | Jul 10, 2029 | |
UnatreneAmpicillin (as Sodium) + Sulbactam(as Sodium) | 500mg/250mg Powder for Injection (IM/IV)USP Type I Glass Vial x 10’s (Box of 10’s) | Rx | Shin Poong Pharmaceutical Co., Ltd.Republic of Korea | Aisec Farma CorporationImporter: Phil Shinpoong Pharma, Inc. | DRP-5442-05 | May 31, 2027 | |
Unazeus 1.5Ampicillin (as sodium) + Sulbactam (as sodium) | 1 g/500 mg Powder for Injection (I.V./I.M.)USP Type II Tubular Glass Vial with Butyl Rubber Stopper and Flip-off Cap (Box of 10’s) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Ambicare Pharmaceuticals Inc. | DRP-11465 | Mar 15, 2032 | |
Unazeus 750Ampicillin (as sodium) + Sulbactam (as sodium) | 500 mg/250 mg Powder for Injection (I. V ./I.M.)USP Type II Tubular Glass Vial with Butyl Rubber Stopper and Flip-off Cap (Box of 10’s) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Ambicare Pharmaceuticals Inc. | DRP-11464 | Mar 15, 2032 | |
UnazilAmpicillin (as sodium) + Sulbactam (as sodium) | 1 g/500 mg Powder for Injection (IM/IV)USP Type I clear glass vial x 10 mL with grey bromobutyl rubber stopper, aluminum seal, and dark beige flip-off cap (Box of 1 finished product + 5 mL Sterile Water for Injection diluent x 1 ampoule); and (Box of 10's; without diluent) | Rx | Friends Pharma (Pvt.) Ltd.Pakistan | Raquel-Abbas Pharmaceuticals & General Merchandise | DRP-17757 | Feb 27, 2032 | |
UnbrandedAmpicillin (as sodium) + Sulbactam (as sodium) | 1 g/ 500 mg Powder for Injection (I.M./I.V.)USP Type I clear Glass Vial Box of 1’s | Rx | Unichem Laboratories LimitedIndia | International Pharmaceuticals, Inc.Importer: Ambica International Corporation | DRP-5079-01 | Feb 11, 2029 | |
UnsinAmpicillin (as sodium) + Sulbactam (as sodium) | 500mg/250mg Powder for Injection (IM/IV)1 USP Type III Glass Vial with secondary box Box of 1's | Rx | 2 World LaboratoriesIndia | 2 World Traders Subic Inc. | DR-XY39162 | Mar 10, 2031 | |
Vactrimed 1.5gAmpicillin (as sodium) + Sulbactam (as sodium) | 1g/500mg Powder for Injection (.M./I.V.)Molded glass vial with butyl rubber stopper and aluminum-plastic cap (Box of 1's) | Rx | North China Pharmaceutical Co., Ltd.China | Asianmeds, Inc.Importer: Euro-Care Products Philippines | DRP-12026-01 | May 31, 2027 | |
Vactrimed 750Ampicillin (as sodium) + Sulbactam (as sodium) | 500 mg / 250 mg Powder for Injection (I.M./I.V.)Molded glass vial with halogenated butyl rubber stopper and aluminum-plastic caps (Box of 1's) | Rx | North China Pharmaceutical Co., Ltd.China | Asianmeds, Inc.Importer: Euro-Care Products Philippines | DRP-12025-01 | May 31, 2027 | |
VigosulAmpicillin (as sodium) + Sulbactam (as sodium) | 500 mg / 250 mg Powder for Injection (IV/ IM)USP Type II glass vial x 10 mL sealed with butyl rubber stopper and aluminum flip-off cap (Box of 1’s) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Vigorous Health Pharma and Medical Supplies TradingImporter: AGlobal Care, Inc. | DRP-12252-05 | Jul 4, 2027 | |
YupitamAmpicillin (as Sodium) + Sulbactam (as Sodium) | 500 mg/ 250 mg Powder For Injection (M/IV)10 mL USP Type II Colorless Glass Vial with rubber stopper and blue flip-off seal + 10 mL Type I Clear Colorless Glass Ampoule Sterile Water for Injection as Diluent (Box of 1's) | Rx | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.China | AMB HK Enterprises Inc. | DRP-8955 | May 17, 2028 | |
ZusillinAmpicillin (as sodium) + Sulbactam (as sodium) | 500 mg/250 mg Powder for Injection (I.M./I.V.)USP Type I Borosilicate Clear Transparent Glass Vial with Butyl Rubber Stopper Sealed with Aluminum Plastic Cap and Blue Flip-Off x 7 mL (Box of 1’s in 10’s) | Rx | NORTH CHINA PHARMACEUTICAL CO., LTD.China | BELLUS LIFE SOLUTIONS, INC.Importer: AGLOBAL CARE, INC. | DRP-8057-01 | Jul 10, 2028 | |
(no brand name)Ampicillin (as sodium) + Sulbactam (as sodium). | 1 g/500 mg Powder for Injection (IM/IV)10 mL-capacity USP Type II glass vial with butyl rubber stopper and flip-off cap (Box of 1's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Khriz Pharma Trading, Inc. | DR-XY49192 | Aug 30, 2029 | |
(no brand name)Ampicillin (as sodium) + Sulbactam (as sodium) | 500 mg/250 mg Powder for Injection (IM/IV)10 mL-capacity USP Type II glass vial with butyl rubber stopper and flip-off cap (Box of 1's) | Rx | Reyoung Pharmaceutical Co., LtdChina | Khriz Pharma Trading, Inc. | DR-XY49191 | Aug 30, 2029 | |
(no brand name)Ampicillin (as sodium) + Sulbactam (as sodium) | 500 mg/250 mg Powder for Injection (IM/IV)USP Type I Glass Vial x 10's (Box of 10's) | Rx | Shin Poong Pharmaceuticals Co., Ltd.Korea | RiteMed Phils., Inc.Importer: Phil Shinpoong Pharma, Inc. | DRP-5442-03 | May 31, 2027 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Warnings/Precautions
Warnings and precautions (US label) US FDA label
WARNINGS Hypersensitivity Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients on penicillin therapy. These reactions are more apt to occur in individuals with a history of penicillin hypersensitivity and/or hypersensitivity reactions to multiple allergens. There have been reports of individuals with a history of penicillin hypersensitivity who have experienced severe reactions when treated with cephalosporins.
Before therapy with a penicillin, careful inquiry should be made concerning previous hypersensitivity reactions to penicillins, cephalosporins, and other allergens. If an allergic reaction occurs, UNASYN should be discontinued and the appropriate therapy instituted. Hepatotoxicity Hepatic dysfunction, including hepatitis and cholestatic jaundice has been associated with the use of UNASYN.
Hepatic toxicity is usually reversible; however, deaths have been reported. Hepatic function should be monitored at regular intervals in patients with hepatic impairment. Severe Cutaneous Adverse Reactions UNASYN may cause severe skin reactions, such as toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome (SJS), drug reaction with eosinophilia and systemic symptoms (DRESS), dermatitis exfoliative, erythema multiforme, and Acute generalized exanthematous pustulosis (AGEP).
If patients develop a skin rash they should be monitored closely and UNASYN discontinued if lesions progress (see CONTRAINDICATIONS and ADVERSE REACTIONS sections). Clostridioides difficile -Associated Diarrhea Clostridioides difficile -associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including UNASYN, and may range in severity from mild diarrhea to fatal colitis.
Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile. C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy.
CDAD must be considered in all patients who present with diarrhea following antibacterial drug use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibacterial drug use not directed against C. difficile may need to be discontinued.
Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.
Drug interactions
| Drug or class | Severity | Effect | What to do |
|---|---|---|---|
| Probenecid | Adjust or monitor | Raises and prolongs ampicillin and sulbactam levels (label). | Usually avoid; monitor if used. |
| Allopurinol | Minor | More skin rash with ampicillin-class drugs (label). | Usually no action; counsel. |
| Aminoglycosides (same syringe or bag) | Minor | Inactivated in vitro when mixed (label). | Give separately. |
Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.
renalcarematters.com, reviewedDrug interactions (US label) US FDA label
Drug Interactions Probenecid decreases the renal tubular secretion of ampicillin and sulbactam. Concurrent use of probenecid with UNASYN may result in increased and prolonged blood levels of ampicillin and sulbactam. The concurrent administration of allopurinol and ampicillin increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving ampicillin alone.
It is not known whether this potentiation of ampicillin rashes is due to allopurinol or the hyperuricemia present in these patients. There are no data with UNASYN and allopurinol administered concurrently. UNASYN and aminoglycosides should not be reconstituted together due to the in vitro inactivation of aminoglycosides by the ampicillin component of UNASYN.
Adverse reactions
Common
- Injection-site pain (IM 16%, IV 3%), thrombophlebitis
- Diarrhea (3%), rash (under 2%)
Serious
- Anaphylaxis; severe skin reactions
- Hepatic dysfunction and cholestatic jaundice
- Clostridioides difficile-associated diarrhea
- Seizures with very high levels
Adverse reactions (US label) US FDA label
ADVERSE REACTIONS Adult Patients UNASYN is generally well tolerated. The following adverse reactions have been reported in clinical trials. Local Adverse Reactions Pain at IM injection site – 16% Pain at IV injection site – 3% Thrombophlebitis – 3% Phlebitis – 1.2% Systemic Adverse Reactions The most frequently reported adverse reactions were diarrhea in 3% of the patients and rash in less than 2% of the patients.
Additional systemic reactions reported in less than 1% of the patients were: itching, nausea, vomiting, candidiasis, fatigue, malaise, headache, chest pain, flatulence, abdominal distension, glossitis, urine retention, dysuria, edema, facial swelling, erythema, chills, tightness in throat, substernal pain, epistaxis and mucosal bleeding. Pediatric Patients Available safety data for pediatric patients treated with UNASYN demonstrate a similar adverse events profile to those observed in adult patients.
Additionally, atypical lymphocytosis has been observed in one pediatric patient receiving UNASYN. Adverse Laboratory Changes Adverse laboratory changes without regard to drug relationship that were reported during clinical trials were: Hepatic: Increased AST (SGOT), ALT (SGPT), alkaline phosphatase, and LDH. Hematologic: Decreased hemoglobin, hematocrit, RBC, WBC, neutrophils, lymphocytes, platelets and increased lymphocytes, monocytes, basophils, eosinophils, and platelets.
Blood Chemistry: Decreased serum albumin and total proteins. Renal: Increased BUN and creatinine. Urinalysis: Presence of RBC's and hyaline casts in urine. Post-marketing Experience In addition to adverse reactions reported from clinical trials, the following have been identified during post-marketing use of ampicillin sodium and sulbactam sodium or other products containing ampicillin.
Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These events have been chosen for inclusion due to a combination of their seriousness, frequency, or potential causal connection to ampicillin sodium and sulbactam sodium. Infections and Infestations: Clostridioides difficile -associated diarrhea (see WARNINGS section).
Blood and Lymphatic System Disorders: Hemolytic anemia, thrombocytopenic purpura, and agranulocytosis have been reported. These reactions are usually reversible on discontinuation of therapy and are believed to be hypersensitivity phenomena. Some individuals have developed positive direct Coombs Tests during treatment with UNASYN, as with other beta-lactam antibacterials.
Gastrointestinal Disorders: Abdominal pain, cholestatic hepatitis, cholestasis, hyperbilirubinemia, jaundice, abnormal hepatic function, melena, gastritis, stomatitis, dyspepsia, and black "hairy" tongue (see CONTRAINDICATIONS AND WARNINGS sections). General Disorders and Administration Site Conditions: Injection site reaction Immune System Disorders: Serious and fatal hypersensitivity (anaphylactic) reactions (see WARNINGS section), Acute myocardial ischemia with or without myocardial infarction may occur as part of an allergic reaction.
Metabolism and Nutrition Disorders: Hypokalemia Nervous System Disorders: Convulsion and dizziness Renal and Urinary Disorders: Tubulointerstitial nephritis Musculoskeletal and Connective Tissue Disorders: Arthralgia Respiratory, Thoracic and Mediastinal Disorders: Dyspnea Skin and Subcutaneous Tissue Disorders: Toxic epidermal necrolysis, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms (DRESS), angioedema, Acute generalized exanthematous pustulosis (AGEP), erythema multiforme, exfoliative dermatitis, urticaria (see CONTRAINDICATIONS and WARNINGS sections), and linear IgA bullous dermatosis.
Monitoring parameters
- CrCl for dose; seizures with high CSF beta-lactam levels (label overdose section); liver tests (history of cholestatic jaundice is a contraindication); rash; diarrhea (CDAD). Kidney
- CrCl for dose
- Liver tests if symptoms
- Rash, diarrhea
Pregnancy considerations
Pregnancy (US label) US FDA label
Pregnancy Reproduction studies have been performed in mice, rats, and rabbits at doses up to ten (10) times the human dose and have revealed no evidence of impaired fertility or harm to the fetus due to UNASYN. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed (see PRECAUTIONS-Drug/Laboratory Test Interactions section).
Breastfeeding considerations
Lactation (US label) US FDA label
Nursing Mothers Low concentrations of ampicillin and sulbactam are excreted in the milk; therefore, caution should be exercised when UNASYN is administered to a nursing woman.
Pharmacokinetics
Key PK parameters
| Time to peak | IM 1 g/0.5 g: ampicillin 8 to 37 mcg/mL, sulbactam 6 to 24 mcg/mL |
|---|---|
| Half-life | About 1 hour for each |
| Half-life in kidney failure (ESKD) kidney | About 5 hours at CrCl 15–29 and 9 hours at CrCl 5–14 (label Table 3) |
| Protein binding | Ampicillin 28%; sulbactam 38% |
| Renal excretion kidney | 75% to 85% of each unchanged in urine in 8 hours |
| Dialyzability kidney | Ampicillin yes; sulbactam probably (label) |
The mean serum half-life of both drugs is approximately 1 hour in healthy volunteers.
Approximately 75 to 85% of both ampicillin and sulbactam are excreted unchanged in the urine during the first 8 hours after administration of UNASYN to individuals with normal renal function.
Mean half-life values were approximately 1 hour.
Pharmacokinetics (US label) US FDA label
CLINICAL PHARMACOLOGY General Immediately after completion of a 15-minute intravenous infusion of UNASYN, peak serum concentrations of ampicillin and sulbactam are attained. Ampicillin serum levels are similar to those produced by the administration of equivalent amounts of ampicillin alone. Peak ampicillin serum levels ranging from 109 to 150 mcg/mL are attained after administration of 2000 mg of ampicillin plus 1000 mg sulbactam and 40 to 71 mcg/mL after administration of 1000 mg ampicillin plus 500 mg sulbactam.
The corresponding mean peak serum levels for sulbactam range from 48 to 88 mcg/mL and 21 to 40 mcg/mL, respectively. After an intramuscular injection of 1000 mg ampicillin plus 500 mg sulbactam, peak ampicillin serum levels ranging from 8 to 37 mcg/mL and peak sulbactam serum levels ranging from 6 to 24 mcg/mL are attained.
The mean serum half-life of both drugs is approximately 1 hour in healthy volunteers. Approximately 75 to 85% of both ampicillin and sulbactam are excreted unchanged in the urine during the first 8 hours after administration of UNASYN to individuals with normal renal function. Somewhat higher and more prolonged serum levels of ampicillin and sulbactam can be achieved with the concurrent administration of probenecid.
In patients with impaired renal function the elimination kinetics of ampicillin and sulbactam are similarly affected, hence the ratio of one to the other will remain constant whatever the renal function. The dose of UNASYN in such patients should be administered less frequently in accordance with the usual practice for ampicillin (see DOSAGE AND ADMINISTRATION section).
Ampicillin has been found to be approximately 28% reversibly bound to human serum protein and sulbactam approximately 38% reversibly bound. The following average levels of ampicillin and sulbactam were measured in the tissues and fluids listed: TABLE 1 Concentration of UNASYN in Various Body Tissues and Fluids Fluid or Tissue Dose (grams) Ampicillin/Sulbactam Concentration (mcg/mL or mcg/g) Ampicillin/Sulbactam Peritoneal Fluid 0.5/0.5 IV 7/14 Blister Fluid (Cantharides) 0.5/0.5 IV 8/20 Tissue Fluid 1/0.5 IV 8/4 Intestinal Mucosa 0.5/0.5 IV 11/18 Appendix 2/1 IV 3/40 Penetration of both ampicillin and sulbactam into cerebrospinal fluid in the presence of inflamed meninges has been demonstrated after IV administration of UNASYN.
The pharmacokinetics of ampicillin and sulbactam in pediatric patients receiving UNASYN are similar to those observed in adults. Immediately after a 15-minute infusion of 50 to 75 mg UNASYN/kg body weight, peak serum and plasma concentrations of 82 to 446 mcg ampicillin/mL and 44 to 203 mcg sulbactam/mL were obtained. Mean half-life values were approximately 1 hour.
MICROBIOLOGY Mechanism of Action Ampicillin is similar to benzyl penicillin in its bactericidal action against susceptible organisms during the stage of active multiplication. It acts through the inhibition of cell wall mucopeptide biosynthesis. Ampicillin has a broad spectrum of bactericidal activity against many gram-positive and gram-negative aerobic and anaerobic bacteria.
(Ampicillin is, however, degraded by beta-lactamases and therefore the spectrum of activity does not normally include organisms which produce these enzymes). A wide range of beta-lactamases found in microorganisms resistant to penicillins and cephalosporins have been shown in biochemical studies with cell free bacterial systems to be irreversibly inhibited by sulbactam.
Although sulbactam alone possesses little useful antibacterial activity except against the Neisseriaceae, whole organism studies have shown that sulbactam restores ampicillin activity against beta-lactamase producing strains. In particular, sulbactam has good inhibitory activity against the clinically important plasmid mediated beta-lactamases most frequently responsible for transferred drug resistance.
Sulbactam has no effect on the activity of ampicillin against ampicillin-susceptible strains. The presence of sulbactam in the UNASYN formulation effectively extends the antibacterial spectrum of ampicillin to include many bacteria normally resistant to it and to other beta-lactam antibacterials. Thus, UNASYN possesses the properties of a broad-spectrum antibacterial and a beta-lactamase inhibitor.
Antimicrobial Activity While in vitro studies have demonstrated the susceptibility of most strains of the following organisms, clinical efficacy for infections other than those included in the INDICATIONS AND USAGE section has not been documented. Gram-positive Bacteria: Staphylococcus aureus (beta-lactamase and non-beta-lactamase producing) Staphylococcus epidermidis (beta-lactamase and non-beta-lactamase producing) Staphylococcus saprophyticus (beta-lactamase and non-beta-lactamase producing) Enterococcus faecalis Streptococcus pneumoniae Streptococcus pyogenes Streptococcus viridans Gram-negative Bacteria: Hemophilus influenzae (beta-lactamase and non-beta-lactamase producing) Moraxella catarrhalis (beta-lactamase and non-beta-lactamase producing) Escherichia coli (beta-lactamase and non-beta-lactamase producing) Klebsiella species (all known strains are beta-lactamase producing) Proteus mirabilis (beta-lactamase and non-beta-lactamase producing) Proteus vulgaris Providencia rettgeri Providencia stuartii Morganella morganii Neisseria gonorrhoeae (beta-lactamase and non-beta-lactamase producing) Anaerobes: Clostridium species These are not beta-lactamase producing strains and, therefore, are susceptible to ampicillin alone.
Peptococcus species Peptostreptococcus species Bacteroides species, including B. fragilis Susceptibility Testing For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fda.gov/STIC.
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Ampicillin + Sulbactam 1.5 g Vial | ₱28.89–₱300.00Reference ₱58.17 | per vial | DPRI procurement range |
| Ampicillin + Sulbactam 500mg + 250 mg Vial | ₱17.88–₱249.90Reference ₱21.14 | per vial | DPRI procurement range |
Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
Formulary and coverage
| Philippine National Formulary | Listed as Ampicillin + Sulbactam |
| PNF listing | Inj.: 500 mg ampicillin + 250 mg sulbactam (IM, IV) (as sodium salt) per vial |
| PNF listing | Inj.: 1000 mg ampicillin + 500 mg sulbactam (IM, IV) (as sodium salt) per vial |
| PNF listing | Inj.: 2000 mg ampicillin + 1000 mg sulbactam (IM, IV) (as sodium salt) per vial |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. UNASYN · Roerig [US FDA-approved label, version 46, July 10, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=155c7ec0-5862-404f-b1d0-f278f8a8bbda
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
- Roerig. (2026). UNASYN (ampicillin sodium and sulbactam sodium) for injection [Prescribing information; US FDA-approved label, NDA050608, set ID 155c7ec0-5862-404f-b1d0-f278f8a8bbda, version effective July 10, 2026]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=155c7ec0-5862-404f-b1d0-f278f8a8bbda
- Li, L., Li, X., Xia, Y., Chu, Y., Zhong, H., Li, J., Liang, P., Bu, Y., Zhao, R., Liao, Y., Yang, P., Lu, X., & Jiang, S. (2020). Recommendation of antimicrobial dosing optimization during continuous renal replacement therapy. Frontiers in Pharmacology, 11, Article 786. https://doi.org/10.3389/fphar.2020.00786
- Li, P. K.-T., Chow, K. M., Cho, Y., Fan, S., Figueiredo, A. E., Harris, T., Kanjanabuch, T., Kim, Y.-L., Madero, M., Malyszko, J., Mehrotra, R., Okpechi, I. G., Perl, J., Piraino, B., Runnegar, N., Teitelbaum, I., Wong, J. K.-W., Yu, X., & Johnson, D. W. (2022). ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment. Peritoneal Dialysis International, 42(2), 110–153. https://doi.org/10.1177/08968608221080586
renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.
Last updated: .